1. Home
  2. Insights
  3. Blog
  4. Navigating psychedelic clinical trials

Navigating psychedelic clinical trials

Operational and regulatory considerations for sponsors

Mental Health Awareness Month recognised during the month of May in the US, provides an opportunity to examine how emerging therapeutic approaches are reshaping clinical research in psychiatry.

As rates of treatment‑resistant mental health conditions remain high, psychedelic‑assisted therapies are drawing increased attention from researchers, regulators, and sponsors seeking novel mechanisms and improved patient outcomes. Alongside this growing interest comes a need to understand the distinctive operational, regulatory, and ethical complexities involved in studying these compounds.

This blog explores key considerations for sponsors navigating psychedelic clinical trials, drawing on lessons from CNS research and highlighting areas where trial execution often diverges from conventional psychiatric studies.

Psychedelics have demonstrated efficacy signals in a number of psychiatric disorders, representing a major shift in how the field thinks about treating patients. Promising results have prompted increased investment in late-stage clinical programmes. However, psychedelic trials present unique operational, regulatory, and methodological challenges that differ markedly from conventional psychiatric studies.  These challenges underscore the importance of informed trial planning, specialist operational expertise, and cross‑functional coordination throughout study design and execution.

Psychedelic trials face a recruitment paradox: patient interest is often unusually high for a CNS indication, but the composition of that interest pool creates protocol problems that CROs must proactively manage. Volunteers for psychedelic studies skew toward individuals with prior psychedelic experience or strong positive treatment expectations — characteristics that directly amplify expectancy effects and functional unblinding. Eligibility criteria in psychedelic studies are also characteristically restrictive. These exclusions drive screen failure rates considerably higher than in standard psychiatry trials. Effective recruitment strategies often rely on enhanced pre‑screening approaches to identify ineligible candidates early and account for higher‑than‑average screen failure rates during budget and timeline planning.

Regulatory requirements for Schedule I controlled substances demand specialised expertise. Sponsors must secure appropriate licensing, implement rigorous chain-of-custody procedures, and ensure compliant storage and dispensing at every site. Delays in licensing can extend startup timelines significantly. In addition, study design must account for the inherent difficulties in maintaining blinding due to the compounds’ pronounced perceptual effects. Expectation bias and functional unblinding are common concerns that require careful mitigation strategies.

Patient monitoring protocols are equally demanding. Sessions typically require extended observation periods of up to twelve hours, supported by trained facilitators and immediate physician availability. The therapeutic setting itself must be optimised for psychological safety, moving beyond standard clinical environments to spaces that promote comfort and trust. Site staff and raters need targeted training to manage acute session dynamics, appropriately identify and report adverse events, and maintain consistency in endpoint assessments.

Running psychedelic trials in the United States versus Europe presents distinct pathways. In the US, the FDA offers a centralised process through an Investigational New Drug application, with a 30-day review period. The agency has been proactive, granting Breakthrough Therapy designations to several psychedelic programmes.

In Europe, trials fall under the EU Clinical Trials Regulation through the Clinical Trials Information System. While this provides a single portal for multi-country submissions, it requires coordinated assessment involving both the EMA and individual member state authorities. Each country may impose additional requirements for controlled substances, leading to greater complexity across borders.

For sponsors advancing psychedelic programmes, success will hinge on more than promising efficacy signals alone. These studies demand a partner with deep CNS experience, controlled‑substance regulatory fluency, and the operational maturity to manage expectancy effects, complex site dynamics, and extended patient interactions without compromising scientific rigour. With the right strategic planning and specialist execution, psychedelic trials can be conducted to the highest regulatory and ethical standards, enabling sponsors to generate credible data, protect patient safety, and accelerate the development of transformative mental health therapies.

In this section

Connect with us